Table 1 Baseline and clinical characteristics of the study patients
Characteristics | No pre-treatment (N = 46, 46.5%) | Pre-treatment (N = 53, 53.5%) | P-value |
|---|---|---|---|
Mean age (years) | 37.1 ± 16.2 | 38.0 ± 12.9 | 0.97 |
Female sex | 22 (47.8) | 19 (35.8) | 0.23 |
Dialysis duration (months) | 64.5 ± 55.0 | 18.6 ± 34.3 | < 0.001 |
Time from FSGS to dialysis or transplantation (months) | 72.3 ± 55.9 | 62.9 ± 68.1 | 0.73 |
Pre-emptive transplantation | 5 (10.9) | 12 (22.6) | 0.12 |
Body mass index (kg/m2) | 21.4 ± 4.0 | 22.7 ± 5.0 | 0.15 |
Pre-transplant treatment | 0.001 | ||
Plasmapheresis only | – | 24 (45.3) | |
Plasmaphereses + rituximab | – | 29 (54.7) | |
ABO-incompatible | 0 (0.0) | 23 (43.4) | N/A |
FCXM-positive | 0 (0.0) | 5 (9.4) | N/A |
HLA-A, B, DR mismatch | 3.0 ± 1.6 | 2.9 ± 1.7 | 0.88 |
PRA class I | 8.8 ± 22.8 | 12.9 ± 26.0 | 0.41 |
PRA class II | 10.5 ± 25.0 | 10.5 ± 23.6 | 0.99 |
Deceased donor | 26 (56.5) | 3 (5.7) | < 0.001 |
Living donor | 20 (43.5) | 50 (94.3) | |
Calcineurin inhibitor | 0.011 | ||
Tacrolimus | 40 (87.0) | 34 (64.2) | |
Cyclosporin | 6 (13.0) | 19 (35.8) | |
Induction | 0.005 | ||
No | 2 (4.7) | 0 (0.0) | |
Basiliximab | 36 (83.7) | 45 (100.0) | |
Anti-thymocyte globulin | 5 (11.6) | 0 (0.0) | |
FSGS recurrence* | 16 (34.8) | 5 (9.4) | 0.002 |
Graft failure due to recurrent FSGS | 3 (6.5) | 0 (0.0) | 0.10 |